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Key messages
 ► inhibition of bromodomain and extra-terminal (BeT) 
proteins (BRD2, BRD3, BRD4) has anti-inflammatory 
effects.
 ► BeT protein inhibition alleviates arthritis and fibrosis.
 ► Bromodomain proteins of distinct families are im-
portant in Th17 cell differentiation.
 ► There is a need for studies beyond the use of 
pan-inhibitors to unravel the role of individual bro-
modomain proteins.
AbstrAct
The reading of acetylation marks on histones by 
bromodomain (BRD) proteins is a key event in 
transcriptional activation. Small molecule inhibitors 
targeting bromodomain and extra-terminal (BeT) proteins 
compete for binding to acetylated histones. They 
have strong anti-inflammatory properties and exhibit 
encouraging effects in different cell types in vitro and in 
animal models resembling rheumatic diseases in vivo. 
Furthermore, recent studies that focus on BRD proteins 
beyond BeT family members are discussed.
InTroduCTIon
Acetylation of histones is associated with the 
establishment of euchromatin, which is a 
prerequisite for the activation of gene tran-
scription and expression. The opposing func-
tions of histone acetyl transferases (HAT) 
and histone deacetylases (HDAC) control the 
acetylation of lysine residues on histones but 
both protein families have also been shown 
to act on non-histone proteins.1 HDAC inhib-
itors have been widely studied in rheumatic 
diseases (RMD) in vitro and in vivo, under-
scoring the importance of protein lysine 
acetylation in this context.2 3
The recognition of ε-N-acetylation modifica-
tions on histones is a key event in the reading 
of epigenetic marks. Bromodomains (BRD) 
exclusively recognise acetylation motifs. BRDs 
form a bundle of four alpha helices, linked 
by interhelical loop regions of variable length 
and sequence that form the hydrophobic 
lysine acetlyation binding site and contribute 
to substrate specificity. The structural features 
of BRDs are in sharp contrast to other epigen-
etic reader domains such as chromodomains 
which hold a β-barrel structure.4 Many BRDs 
have good druggability, based on prediction 
from available structures and computational 
analysis.5 Frequently, BRDs are flanked by 
several other epigenetic reader domains, in 
multidomain BRD proteins, or they occur 
in tandem arrangement in bromodomain 
and extra-terminal domain (BET) proteins 
(BRD2, BRD3, BRD4, BRDT).6
Reading of acetylation marks by BRD 
enables the regulation of gene expression 
through a wide range of activities. Either 
BRD proteins act as scaffolds that enable the 
recruitment and binding of large protein 
complexes or they function as transcription 
factors and coregulators themselves. Addi-
tionally, BRD proteins can contain several 
catalytic domains enabling them to act as 
methyltransferases, ATP-depending chro-
matin remodelling complexes or HATs and 
helicases.7
Involvement of Brd proteins in diseases
The human genome encodes 61 BRDs that 
are present in 46 diverse proteins. These 
proteins cluster into eight major BRD fami-
lies (I–VIII),6 with BET proteins being the 
foremost studied group. Dysfunction of BRD 
proteins has been linked to the develop-
ment of several diseases. Mutations in BRD 
proteins, copy number alterations, misex-
pression and BRD-containing fusion proteins, 
resulting from chromosomal translocation, 
were observed in several cancers.7 Targeting 
BRD proteins has transitioned to the centre 
of epigenetic drug development in the last 
decade. Even some of the beneficial effects of 
HDAC inhibitors might be attributed to BRD, 
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Figure 1 Inhibitors and their chemical structures targeting 
BET proteins. BD2, bromodomain 2; BET, bromodomain and 
extra-terminal.
Figure 2 Inhibitors, such as JQ1 and I-BET, targeting BET 
proteins compete with the BRD for binding to acetylated  
histones. Thereby, they prevent the transcription of their 
target genes depending on the cell type. This leads to 
decreased proliferation, suppressed cell differentiation and 
maturation and altered gene expression. BET inhibitors 
lead to decreased inflammation, cartilage destruction, bone 
resorption and fibrosis. AC, acetylated; BET, bromodomain 
and extra-terminal; BRD, bromodomain; col, collagen; MMP, 
matrix metalloproteinase; αSMA, alpha smooth muscle cell 
actin.
since HDAC inhibitors can induce a selective depletion 
of BRD proteins from the cells’ nuclei.8
BET protein inhibitors
In 2010, the first small molecule inhibitors targeting 
BET proteins, JQ1 and I-BET, have been described by 
Filippakopoulos et al and Nicodeme et al, which exhib-
ited anticancer and anti-inflammatory activities, respec-
tively.9 10 The availability of inhibitors has led to a signif-
icant increase in the BRD protein research. BET inhib-
itors (figure 1), targeting BRD2, BRD3, BRD4, and the 
testis-specific BRDT have been tested in many cell types, 
diseases and disease models suggesting a role of BET 
proteins far beyond cancer, such as inflammation,10–18 
fibrosis,19–23 asthma 24 25 , coronary artery26 and cardio-
vascular disease,27 28 Alzheimer’s disease,29 30 autism-like 
syndrome,31 graft-versus-host disease32 and a variety of 
autoimmune conditions.33–37 BET inhibitors bind to 
the proteins’ BRD, compete for binding to acetylated 
histones and displace BET proteins from nuclear chro-
matin. This prevents the transcription of BRD protein 
target genes (figure 2). By now, at least 14 different small 
molecule inhibitors targeting BRD proteins have entered 
clinical trials for different forms of cancer, but also for 
the treatment of type 2 diabetes mellitus, cardiovascular 
disease and coronary artery disease.7 10
The most-studied member among BET proteins is BRD4. 
BRD4 confers the ability to direct the assembly of HAT-de-
pendent chromatin complexes (figure 3), leading to the 
recruitment of positive transcription elongation factor b 
(p-TEFb)38 39 and subsequent phosphorylation of RNA 
polymerase II (RNA Pol II).40 Additionally, p-TEFb-inde-
pendent transcriptional activation via the extra-terminal 
domain of BRD4 has been shown.41 BRD4 has also kinase 
activity and binds and phosphorylates RNA Pol II42 and 
acetylates H3K122, a residual critical for nucleosome 
stability, whose acetylation leads to histone eviction.43 
Furthermore, by binding BRD4 to the acetylated lysine-
310 of p65, BRD4 regulates the transcriptional activity of 
nuclear factor kappa light chain enhancer of activated B 
cells (NF-κB). This interaction was shown to be sensitive 
to treatment with JQ1, which induced the ubiquitination 
and subsequent degradation of the constitutively active 
nuclear form of p65.44 This data suggests an active role 
of BRD4 in transcription. Recent work has demonstrated 
the recruitment of BRD4 to enhancers45 and its involve-
ment in assisting transcriptional elongation at enhancers 
(enhancer RNA (eRNA)) and gene bodies.46 Therefore, 
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Figure 3 By binding to acetylated histones, BRD4 contributes to the assembly of histone acetyltransferase-dependent 
chromatin complexes at gene promoters and to the recruitment of TF and p-TEFb. This leads to the phosphorylation of RNA 
Pol II. BRD4 binds also acetylated histones in enhancers and assists transcriptional elongation at enhancers and gene bodies. 
AC, acetylated; BRD4, bromodomain protein 4; P, phosphorylation; p-TEFb, positive transcription elongation factor B; RNA Pol 
II, RNA polymerase II; TF, transcription factors; TSS, transcriptional start site.
BET inhibitors have the potential for a dual targeting of 
gene expression in RMD, by affecting the inflammatory 
environment and by altering cell-type specific enhancer 
activity.9 47 Treatment with JQ1 was shown to preferen-
tially affect the expression of super enhancer-associated 
gene transcripts compared with genes associated with 
bound BRD4 to normal enhancers.47 Super enhancers 
are cell type specific and consist of clusters of enhancers 
that span a long range of DNA (>10 kb). They are densely 
occupied by master transcription factors and histone 
marks and often guide eRNA expression.48 49 Super 
enhancers were demonstrated to specifically regulate 
genes associated with cell identity and disease.47 Tumour 
necrosis factor alpha (TNFα) was shown to be sufficient 
to alter the enhancer landscape of vascular endothelial 
cells, with a BRD4 eviction from basal super enhancers 
and a redistribution to de novo enhancers as well as super 
enhancers in a p65-dependent manner.50 Also, I-BET was 
reported to primarily affect the expression of genes from 
de novo enhancers, whereas promoters enriched for 
histone 3-acetylation and histone 4-acetylation already 
at basal levels (primed loci) were less affected.10 Like-
wise, a disease-specific, inflammation-associated super 
enhancer signature was identified in synovial fluid-de-
rived CD4+ memory/effector T cells from patients with 
juvenile idiopathic arthritis (JIA). JQ1 treatment of 
these cells inhibited immune-related super enhancer 
activity and preferentially suppressed disease-associated 
gene expression. In contrast, the enhancer signature of 
peripheral blood-derived CD4+ memory/effector T cells 
from patients with JIA was relatively similar to those from 
healthy controls and less affected by JQ1 treatment.51 It 
remains to be elucidated whether the altered enhancer 
profile is causally related to disease pathogenesis or the 
consequence of the exposure to a chronic inflammatory 
milieu.
BET inhibitors can target a variety of cell types in RMD 
and have been tested in different mouse models resem-
bling different aspects of RMD (table 1). Several different 
compounds are used in RMD research. Inhibitors in this 
review are named based on their description in the respec-
tive original paper. BET inhibitors block the maturation 
and differentiation of several cell types, including T cell 
subsets,33 34 52 53 dendritic cells54 and osteoclasts.55 56 BRD 
protein members of three distinct families have been 
shown to interfere with the differentiation and function 
of Th17 cells,34 37 52 57 58 suggesting a broad role of BRD 
proteins in autoimmune disorders. Furthermore, BET 
inhibitors affect the inflammatory responses of B cells,59 
macrophages,10 11 13 synovial fibroblasts (SF)15 60 61 and 
chondrocytes.62 63
BET protein inhibition in macrophages
Treatment of murine bone marrow-derived macrophages 
(BMDM) with I-BET or JQ1 suppressed the expression 
of key lipopolysaccharide (LPS)-inducible cytokines, 
chemokines and transcription factors.10 11 13 In line with 
the in vitro data, injection of I-BET or JQ1 before the 
initiation of LPS-induced or Salmonella typhimurium-in-
duced endotoxic shock was able to prevent or attenuate 
death of mice.10 11 Anti-inflammatory effects of BET inhib-
itors were later also confirmed in human monocytes,36 64 
where I-BET151 diminished both autocrine interferon 
(IFN)-β production and transcriptional responses to 
IFN-β.64 Some of these effects might be attributed to the 
function of BRD3, since the knockout of BRD3 in murine 
RAW246.7 macrophages inhibited the virus-triggered 
IFN-β production.65
Whereas whole transcriptome data is available of 
LPS-stimulated BMDM treated with I-BET10 or JQ1,13 
respectively, very little is known on the individual roles of 
BRD2, BRD3 and BRD4 on regulating the inflammatory 
response of BMDM and only few direct target genes are 
known. Individual silencing of BRD2, BRD3 and BRD4 in 
BMDM was sufficient to decrease the LPS-induced expres-
sion of interleukin (IL)6, IL1β, TNFα and monocyte 
chemoattractant protein-1.10 11 The expression of these 
genes was also significantly decreased in LPS-stimulated 
BMDM derived from brd2 lo mice, a genetically modified 
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Table 1 Inhibitors targeting BET proteins have been tested in animal models resembling diverse characteristic of rheumatic 
diseases
Animal model Inhibitor Administration References
Arthritis
  CIA (mouse) JQ1 intraperitoneal Mele et al34
  CIA (mouse) JQ1 n.d. Zhang et al67 
  CIA (mouse) JQ1 intraperitoneal Xiao et al60 
  CAIA (mouse) RVX-297 oral Jahagirdar et al37 
  CIA (mouse, rat) RVX-297 oral Jahagirdar et al37 
  K/BxN serum transfer (mouse) I-BET151 intraperitoneal Park-Min et al55 
Osteoporosis
  OVX (mouse) I-BET151 intraperitoneal Park-Min et al55 
Osteoarthritis
  DMM (mouse) I-BET151 intraperitoneal Dai et al62 
Systemic lupus erythematosus
  MRL-lpr (mouse) JQ1 oral Wei et al36 
Psoriasis
  IMQ (mouse) JQ1 topical Nadeem et al77 
Ankylosing spondylitis
  HLA-B27/β2m (rat) I-BET151 intraperitoneal Fan et al82 
Fibrosis
  Bleomycin (mouse) JQ1 oral (chow) Tang et al85 
  Bleomycin (mouse) JQ1 oral (chow) Tang et al22 
  UUO (mouse) I-BET151 intraperitoneal Xiong et al23 
  TAD (mouse) JQ1 intraperitoneal Duan et al20 
  LAD (mouse) JQ1 intraperitoneal Duan et al20 
  CCl4 (mouse) JQ1 intraperitoneal Ding et al19 
BET, bromodomain and extra-terminal; CAIA, collagen antibody induced arthritis; CCl4, carbon tetrachloride; CIA, collagen-induced 
arthritis; DMM, destabilisation of the medial meniscus; HLA, human leucocyte antigen; IMQ, imiquimod; LAD, left anterior descending; 
n.d., not defined; OVX, ovariectomy; TAD, transverse aortic constriction; UUO, unilateral ureteral obstruction.
mouse model with a hypomorph phenotype and a 50% 
reduction of BRD2 expression in all tested tissues.11
Chromatin immunoprecipitations (ChIP) of TNFα and 
IL6 promoter regions in BMDM identified first gene-spe-
cific and distinct mechanisms behind BRD2 and BRD4 
functions. Whereas BRD2 and BRD4 bound to the IL6 
promoter, the TNFα promoter was bound only by BRD2 
but not by BRD4. Since silencing of BRD4 was suffi-
cient to decrease the TNFα secretion in LPS-stimulated 
BMDM, a chromatin-independent effect of BRD4 was 
suggested by the authors.11 Some of the anti-inflamma-
tory effects of BET inhibitors might also be mediated by a 
direct effect of BET inhibitors on the activation of NF-κB 
pathways by decreasing the TNFα-induced phosphory-
lation of NF-κB inhibitor α (IκBα).12 66 However, these 
effects were not consistently observed and might be cell-
type dependent or related to the treatment protocol and 
inhibitor used.10 15 60
BET protein inhibition in synovial fibroblasts
Besides the anti-inflammatory role of BET inhibitors in 
macrophages, I-BET151 and JQ1 were also sufficient to 
decrease the TNFα-induced, IL1β-induced, as well as the 
Toll-like receptor ligand-induced inflammatory response 
of SF and to decrease SF proliferation.15 60 61 The changes 
in gene expression of cytokines and chemokines trans-
lated into a reduced chemoattractance towards periph-
eral blood mononuclear cell.15 Silencing of BRD2 
or BRD4 was equally efficient in downregulating the 
TNFα-induced expression of matrix metalloproteinases 
(MMP) and cytokines in SF.60 In addition, BRD4 was 
shown to control migration and invasion of SF.67 Similar 
to macrophages, only few target genes of individual BET 
proteins are known in SF. Recently, a study by Nagpal et 
al provided new insights into the mechanisms behind the 
activity of JQ1 in SF. JQ1 was shown to reduce the occu-
pancy of both BRD2 and BRD4 in approximately 2000 
regions and RNA Pol II in approximately 600 regions 
genome-wide in IL1β-treated SF. The authors showed 
that JQ1 reduced the BRD2/BRD4 occupancy in the IL6 
and IL8 super enhancer regions in SF,61 consistent with a 
general function of BET proteins on super enhancers in 
different cell types.50 51 68 69
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Besides the regulatory function of BET proteins in SF 
under inflammatory conditions, BET reading regulated 
the expression of HOX genes in a joint-specific manner 
under non-inflammatory conditions. I-BET151 decreased 
the basal expression of genes encoded in the 5′ HOXA 
cluster, but not of genes encoded in the 5′ HOXC cluster, 
which distinguish SF derived from upper versus lower 
extremity joints.70 This might be relevant to arthritis, 
since the expression of specific HOX genes widely over-
laps with the occurrence of certain forms of arthritis in 
specific joints.71 As an exception among BRD proteins, 
BRD4 was shown to stick to the chromatin during mitosis 
in murine P19 embryonal carcinoma cells.38 This feature 
makes BET proteins to the key candidates that maintain 
the transcriptional memory in SF and other cells.
BET protein inhibition in endothelial cells
Endothelial cell activation and dysfunction are hall-
marks of systemic autoimmune diseases such as rheuma-
toid arthritis, systemic lupus erythematosus (SLE) and 
systemic sclerosis (SSc).72–74 JQ1 treatment or silencing of 
BRD2 or BRD4 in human umbilical vein endothelial cells 
(HUVEC) suppressed the vascular endothelial growth 
factor (VEGF)-induced tube formation, vascular hyper-
permeability and migration. The effects were accompa-
nied with a reduced VEGF-induced phosphorylation of 
VEGF receptor 2 (VEGFR2), p21-activated kinase 1 and 
endothelial nitric oxide synthase, factors which are impor-
tant for angiogenesis and permeability.75 In addition, 
BET BRD inhibition was shown to efficiently block the 
endothelial activation under inflammatory conditions. 
JQ1 or silencing of BRD2 and BRD4 in HUVEC cells 
suppressed the TNFα-induced or LPS-induced expres-
sion of adhesion molecules, translating into a reduced 
adhesion of leukocytes to activated HUVEC. Pretreat-
ment of HUVEC with JQ1 suppressed the TNFα-induced 
phosphorylation and degradation of IκBα and reduced 
the nuclear levels of p65, indicating that the observed 
effects were at least partially due to a reduced activa-
tion of the NF-κB pathway.16 In line with this data, JQ1 
decreased the p65 recruitment to IL6 and IL8 promoters 
in serum-stimulated human pulmonary microvascular 
endothelial cells (HPMEC), reducing the expression 
and secretion of IL6 and IL8. Furthermore, JQ1 reduced 
HPMEC proliferation, with increased expression of 
cyclin-dependent kinase (CDK) inhibitors CDKN1A and 
CDKN2D and decreased expression of CDK2, CDK4 and 
CDK6.76
BET inhibitors in mouse models of arthritis
As a proof of concept for the use of BRD inhibitors in 
RMD in vivo, in 2013, Mele et al showed that intraperito-
neal injections of JQ1, over a period of 2 weeks, protected 
mice from collagen-induced arthritis (CIA), evident by 
reduced arthritis scores and histological assessment.34 
These findings were later confirmed by two other 
groups.60 67 Recently, the use of a BDR2 specific and orally 
active BET inhibitor, RVX-297, was shown to be efficient 
in decreasing the arthritis scores in CIA mice and rats, as 
well as in mice with collagen antibody-induced arthritis.37 
The beneficial effects of BET inhibitors in arthritis models 
in vivo were mainly attributed to the suppressive effects 
on Th17 cell differentiation and the reduced expression 
of Th17-associated cytokines, including IL17, IL21 and 
granulocyte macrophage-colony stimulating factor.34 37 
The aberrant generation and activation of Th17 cells, a 
subset of T helper cells, is one of the key mechanisms 
leading to autoimmune conditions.53 JQ1 or a combined 
silencing of BRD2 and BRD4 also interfered with the 
differentiation of human Th17 cells and suppressed the 
expression of steroid receptor-type nuclear receptors 
(ROR)A and RORC, encoding the transcription factors 
RORα and RORγt that drive Th17 differentiation, as well 
as IL17A and IL21.34 These findings were later confirmed 
by differentiating Th17 from CD4+ T cells derived from 
healthy controls, patients with ankylosing spondylitis (AS) 
and psoriatic arthritis in the presence and absence of JQ1. 
In the same study, CBP30, a selective CBP/p300 inhibitor 
was described as a suppressant of human Th17 responses. 
In comparison to JQ1, CBP30 affected the expression of 
fewer genes in CD4+ T cells, but similarly downregulated 
the expression of RORC, IL17A and IL21.52 JQ1 was 
also shown to interfere with the RORC/IL17 pathway in 
imiquimod (IMQ)-induced skin inflammation, a mouse 
model for psoriasis-like skin disease. Topical application 
of JQ1 before and after IMQ-induced skin inflammation 
exhibited protective effects as indicated by reduced ear 
thickness, ear myeloperoxidase activity and decreased 
skin expression of RORC and IL17A.77
Mele et al showed that JQ1 had no impact on the differ-
entiation of T cell subsets other than Th17 from human 
naive T cells, such as Th1, Th2 or regulatory T cells.34 In 
contrast, the administration of I-BET762, in early phases 
of T cell differentiation from naive murine T cells had 
long-lasting effects on the proinflammatory function of 
murine Th1 cells accompanied by an increase of anti-in-
flammatory genes such as IL10. Furthermore, I-BET762 
did not affect the expression of RORC in this study, 
but was sufficient to reduce the expression of IL17A.33 
In a doxicyclin-inducible mouse model for sustained 
and reversible silencing of BRD4 in vivo, the absence of 
BRD4 interfered with a normal haematopoiesis, leading 
to a depletion of CD4+ and CD8+ single-positive T cell 
subsets, as well as a significant reduction in Lineage−S-
ca1+cKit+ haematopoietic stem cells in reconstituted bone 
marrow.78 Differences in the results of the differentiation 
of different T cell subsets on BET inhibition might be 
due to different experimental setups or different inhib-
itors and inhibitor concentrations used. Bolden et al, 
for example, showed that the levels of BRD4 silencing 
(moderate vs strong) were essential in obtaining pheno-
typic changes in the intestine of mice.78
BET inhibitors in mouse models of SLE
Oral administration of JQ1 decreased the glomerular 
damage, nephritis, delayed the onset and decreased the 
 o
n
 17 M
ay 2019 by guest. Protected by copyright.
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2018-000744 on 16 Novem
ber 2018. Downloaded from
 
6 Klein K. RMD Open 2018;4:e000744. doi:10.1136/rmdopen-2018-000744
RMD Open
severity of proteinuria in MRL-lpr mice, a murine model 
for SLE. The effects were accompanied by decreased 
serum concentrations of B-cell activating factor, IL1β, 
IL6, IL17 and IFNγ and augmented IL10. In addition, 
JQ1 treatment decreased serum concentrations of anti-
dsDNA antibodies, as well as immune complex deposi-
tion in kidneys,36 a hallmark of human SLE. This is in 
line with the finding that BRD4 interacts with octam-
er-binding transcription factor 2 (Oct2), which is crucial 
for B-cell specific gene expression. JQ1 reduced the 
binding of Oct2 to the immunoglobulin kappa locus 
(IGK) promoter, leading to a BET inhibitor-mediated 
decrease in immunoglobulin production in B cells.59 
In contrast to the study by Wei et al,36 the expression of 
LPS-induced IL10 was decreased in regulatory B cells 
(Breg) by JQ1 treatment.
79 This might represent a detri-
mental effect of JQ1, since Breg cells are critically involved 
in suppression of inflammation and known to inhibit 
inflammatory immune diseases including CIA.80
BET proteins in bone homeostasis and cartilage metabolism
BET proteins have been suggested to play a role in bone 
homeostasis, which is regulated by bone-resorbing oste-
oclasts and bone-synthesising osteoblasts.81 I-BET151 
and JQ1 suppressed the human and mouse nuclear 
factor κB ligand (RANKL)-induced osteoclastogenesis 
in vitro and in vivo.12 55 Therapeutic dosing of I-BET151 
was sufficient to increase bone mass in postovariec-
tomy osteoporosis. In K/BxN serum-induced arthritis, 
a mouse model resembling the inflammatory effector 
phase of arthritis, I-BET151 suppressed bone resorp-
tion, possibly by targeting osteoclast differentiation 
along with suppressing the ongoing inflammation. 
I-BET151 was shown to target nuclear factor of activated 
T cells C1, the master regulator of osteoclastogenesis 
by suppressing MYC.55 In the same study, the authors 
showed that I-BET151 could inhibit the differentiation 
of osteoblasts in vitro by using fivefold to 10-fold higher 
concentrations than those required for the suppression 
of osteoclastogenesis.55 In another study, I-BET151 inhib-
ited the expression of MMP3, MMP9, RANKL and osteo-
protegerin in human MG63 osteoblast cells treated with 
serum derived from patients with AS. The expression of 
these genes was also suppressed in HLA-B27/β2m trans-
genic AS Lewis rats, a rodent model for AS, on treatment 
with I-BET151.82 Unfortunately, no other outcomes of 
I-BET151 were studied in this animal model. Both, JQ1 
and I-BET151 were shown to exhibit protective effects 
on cartilage, by downregulating the expression of major 
factors involved in extracellular matrix degradation in 
human, murine and rat chondrocytes.62 63 On surgical 
destabilisation of the medial meniscus (DMM), postsur-
gical treatment with I-BET151 from day 2 on prevented 
articular cartilage damage, but only at earlier and not at 
later time points after treatment.62 Whether this timely 
limited effect of I-BET151 in the DMM model was due to 
a general suppression of inflammation or other mecha-
nisms was not further studied.
BET proteins in fibrosis
Fibrosis of the skin and internal organs, as well as vascu-
lopathy are hallmarks of SSc.83 Transforming growth 
factor β (TGFβ) and downstream mothers against decap-
entaplegic homolog (SMAD) signalling molecules are 
key factors mediating the disease.84 Inhibition of BET 
proteins was efficient to inhibit lung,22 85 liver,19 renal23 
and heart fibrosis20 in vivo.
Treatment of human dermal fibroblasts (DF) with 
JQ1 decreased the expression of alpha smooth muscle 
cell actin (αSMA), fibronectin, collagen (COL) 1A1, 
nicotinamide adenine dinucleotide phosphate oxidase 
(NOX)421 and TGFβ-induced cytokine secretion.85 
Silencing of BRD4 in DF reduced stress fibre formation 
and resembled the effects on gene expression that were 
observed by JQ1 treatment at least partially.21 Therefore, 
some other BET proteins might additionally be involved 
in the beneficial effects mediated by JQ1 in DF. In pancre-
atic stellate cells, which are key regulators of the collagen 
I production and fibrosis in pancreatic ductal adenocar-
cinoma, silencing of BRD4 suppressed the expression 
of COL1A1 and COL1A2, whereas silencing of BRD2 or 
BRD3 led to opposite effects in this cell type. However, 
JQ1 was still sufficient to suppress collagen production in 
vitro and in vivo.86
In lung fibroblasts, both JQ1 and I-BET or silencing 
of either BRD2 or BRD4, decreased the TGFβ-induced 
expression of αSMA.22 Administration of JQ1 with the 
chow to mice with bleomycin-induced fibrosis prevented 
lung fibrosis.22 85 The expression of BRD4 was shown to 
be elevated in tubular and interstitial cells in humans 
with kidney disease, as well as in kidneys of mice with 
renal fibrosis induced by unilateral ureteral obstruction 
(UUO). Treatment of renal interstitial fibroblasts with 
I-BET151 or silencing of BRD4 reduced the TGFβ-in-
duced expression of αSMA, fibronectin and COL1. In line 
with this, I-BET151 alleviated renal fibrosis in the UUO 
model.23 BET protein inhibition with JQ1 was also suffi-
cient to suppress innate inflammatory and profibrotic 
transcriptional networks in mice subjected to transverse 
aortic constriction and in mice with permanent surgical 
ligation of the proximal left anterior descending coronary 
artery, resembling severe heart failure from prolonged 
pressure overload and massive anterior myocardial infarc-
tion, respectively. Together these data suggest beneficial 
effects of BET protein inhibition in multiorgan fibrosis 
and BRD4 as the major target in this context.
BrPF proteins in rMd
Studies on other BRD proteins than BET proteins in 
RMD are very rare. Recently, two studies on the role of 
BRD and plant homeodomain finger-containing (BRPF) 
family proteins were published. The BRPF family consists 
of three members: BRPF1, BRPF2 (BRD1) and BRPF3. 
BRPF proteins comprise several functional domains 
in addition to a BRD, including two plant homeodo-
mains connected by a zinc finger and a PWWP domain.6 
Pharmacological inhibition of BRPF proteins using the 
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three pan-BRD-inhibitors PFI-4, OF-1 and NI-57 strongly 
impaired RANKL-induced differentiation of murine and 
human primary monocytes into bone resorbing osteo-
clasts accompanied by a decreased expression of osteo-
clast markers.56 In synovial tissues, BRPF2 expression was 
verified in SF and macrophages. BRPF2 exerts cell-type 
and stimulus-specific effects in SF and monocyte-de-
rived macrophages (MDM). Silencing of BRPF2 in SF 
decreased proliferation and led to rather proinflamma-
tory and prodestructive effects. In contrast, silencing of 
BRPF2 in human MDM exhibited mild anti-inflamma-
tory effects, indicated by a decrease of the LPS-induced 
expression of TNFα.87 This data underscore the need for 
careful testing of BRD protein function and their inhibi-
tion in more than one cell type.
TrIM proteins in rMd
Another interesting group of BRD proteins is a subgroup 
of tripartite motif (TRIM) family proteins. TRIM 
proteins are multidomain proteins and are implicated 
in innate signalling pathways.88 Among TRIM proteins, 
TRIM28, TRIM33, TRIM24 and TRIM66 contain a BRD 
and are known as positive and negative transcriptional 
regulators.6 So far, no specific inhibitors targeting these 
TRIM proteins are available but an inhibitor with a dual 
activity targeting the BRD of BRPF1B and TRIM24 has 
been described.89 Knockdown of TRIM28 in human 
macrophages potentiated the IFN-regulatory factor 
5-mediated expression of TNFα.90 Another study showed 
that TRIM33 is overexpressed in muscle and skin tissues 
of patients with dermatomyositis and skin tissues from 
patients with other autoimmune diseases including psori-
asis.91 Studies in knockout mice revealed that TRIM33 
acts as a transcriptional repressor in macrophages in vitro 
and in vivo, leading to a high sensitivity to endotoxin 
challenge. At early stages of haematopoiesis, TRIM33 
deficiency was associated with an impaired production 
of monocytes/macrophages. Deficiency of TRIM33 in 
mature myeloid cells increased the expression of a subset 
of known LPS-repressible genes, whereas the expression 
of only few LPS-inducible genes was decreased.92 In addi-
tion, studies in mice showed that TRIM33 and TRIM28 
play a crucial role in the differentiation of Th17 cells. The 
knockout of TRIM33 or TRIM28 in CD4+ T cells reduced 
the expression of IL17 and IL17F but had, in contrast to 
the BET protein-regulated inhibition of Th17 differentia-
tion, no effect on Th17-related transcription factors such 
as RORC.57 58 These data point to different mechanisms 
underlying the BET protein-mediated and TRIM-me-
diated Th17 differentiation. In the absence of TRIM33 
or TRIM28, the IL17 locus was enriched for suppressive 
histone marks, or reduced in active epigenetic marks, 
respectively, whereas the IL10 locus was enriched for 
activating H3K4me3 in TRIM33 knockout cells, leading 
to decreased and increased expression of the respective 
genes.57 58 TRIM33 orchestrated its effects by forming a 
transcriptional complex with RORγt and Smad2.57 On the 
other hand, a STAT3-dependent recruitment of TRIM28 
was required for the RORγt recruitment and function at 
the IL17-IL17F locus.58
ConCLuSIon and ouTLook
The development of small molecule inhibitors targeting 
BET proteins has raised new possibilities in the future 
treatment of RMD. Their effects among different mouse 
models are encouraging and raise the perspective that 
BET inhibitors might be used in the future for the treat-
ment of different RMD including their comorbidities, 
such as cardiovascular events or chronic obstructive 
pulmonary disease. Preclinical and basic research studies 
provide indication of potential complications of BET 
inhibitor therapies, such as sterility, retroviral activation 
and impact on the haematopoietic development. The 
latter concern was confirmed by results of first phase 
1 clinical studies in patient cohorts with lymphoma or 
multiple myeloma and patients with acute leukaemia 
( ClinicalTrials. gov, number NCT01713582). These 
studies reported reversible haematological toxicities, in 
particular thrombocytopenia, anaemia and neutropenia 
as the main related adverse events that were frequent 
among all dose levels. Few non-haematological events 
were reported, including gastrointestinal events and 
fatigue with increasing frequency and severity at the 
highest doses.93 94 Given that common BET inhibitors 
might be considered as non-hormonal approach to male 
contraception and also target the testis-specific BRDT 
protein, a BET protein essential for spermatogenesis, 
one of the adverse effects of BET inhibitor treatment 
could be male sterility.95–97 In addition, BET inhibitors 
are capable of reactivating latent retroviral gene expres-
sion.98 99 Although the exact role of retroviruses in RMD 
is incompletely understood, there is consensus about 
their role as triggers of autoimmunity 100 101 . Therefore, 
the use of BET inhibitors in patients with RMD might 
bear an unpredictable risk.
Ten years after the first publication of BET inhibitors, 
there is still remarkably little known on individual func-
tions of single BET proteins. The majority of research has 
focused on the use of pan-BET inhibitors in different cell 
types in vitro and in mouse models in vivo and only few 
studies do a more in depth analysis on the underlying 
mechanisms of BET protein inhibition. Some studies have 
identified small numbers of target genes of selected BET 
proteins, mainly of BRD4, but full transcriptome analysis 
of BET proteins in different cell types and conditions are 
missing. Recent studies focused on the oral administra-
tion of BET inhibitors36 37 85 or the use of BRD2-selective 
inhibitors such as RVX-297.37 The good druggability of 
BRD will likely lead to the continuing development of 
inhibitors that will further boost the research in this field.
Studies on BRD proteins outside of the BET protein 
family are only appearing in the last few years and are 
still rare. Inhibitors targeting BRPF family proteins have 
only recently been developed 56 102 103 and will likely boost 
the research on BRPF proteins also in the field of RMD. 
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So far, no TRIM protein-specific inhibitors are available 
for research, likely due to their dual function as activators 
and repressors of transcription. However, the interfer-
ence of TRIM proteins with the differentiation of Th17 
cells suggests that also TRIM protein inhibition might be 
a successful treatment in autoimmune conditions.
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